Rotigotine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Rotigotine
- Rotigotine: From Parkinson's Disease/Restless Legs Syndrome to Attention Deficit-Hyperactivity Disorder
Rotigotine: From Parkinson's Disease/Restless Legs Syndrome to Attention Deficit-Hyperactivity Disorder
One-Sentence Summary
Rotigotine is a dopamine D1/D2/D3 receptor agonist established for Parkinson's Disease and Restless Legs Syndrome (RLS). The TxGNN model predicts it may be effective for Attention Deficit-Hyperactivity Disorder (ADHD), but currently no clinical trials and only 3 indirect publications support this specific direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Parkinson's Disease / Restless Legs Syndrome (per PMID 37221270; not derivable from Taiwan/Germany license data, which is empty) |
| Predicted New Indication | Attention Deficit-Hyperactivity Disorder (ADHD) |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data from DrugBank is currently a [High-severity data gap] and was not available for this evaluation (DG002). Based on the evidence pack's literature, Rotigotine is known as a non-ergot D1/D2/D3 dopamine receptor full agonist, used clinically for Parkinson's Disease and RLS (PMID 37221270).
The mechanistic link to ADHD is indirect. ADHD pathophysiology does involve dopaminergic dysregulation, but the standard-of-care drugs (methylphenidate, amphetamine) act by increasing synaptic dopamine/norepinephrine concentrations, not by direct receptor agonism. The literature retrieved for this candidate does not address ADHD directly — one paper covers RLS (a condition with known ADHD comorbidity), and another is basic receptor pharmacology on D4 receptor heterodimerization implicated in ADHD genetics, not a Rotigotine efficacy study.
Notably, a second predicted indication in this evidence pack — schizophrenia (rank 2, TxGNN score 99.996%) — has comparatively stronger support: a systematic review/meta-analysis (PMID 31688399) on prodopaminergic drugs for negative symptoms of schizophrenia, plus a structural biology paper (PMID 37221270) directly showing Rotigotine bound to all five dopamine receptor subtypes. This suggests the schizophrenia hypothesis may merit prioritized follow-up over ADHD, though neither has a Rotigotine-specific clinical trial.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21476956 | 2011 | Review | Current Pharmaceutical Design | Reviews pharmacological options for RLS in children; RLS and ADHD frequently co-occur, but does not evaluate Rotigotine for ADHD directly |
| 34182128 | 2021 | Preclinical/Receptor pharmacology | Pharmacological Research | Shows α2A adrenoceptor–D4 receptor heteromerization affects impulsive-control disorder pharmacology, relevant to ADHD biology but not to Rotigotine specifically |
| 18656214 | 2008 | Review | Revue Neurologique | General review of RLS pathophysiology and treatment; no ADHD-specific data |
Safety Considerations
Please refer to the package insert for safety information.
(Key warnings, contraindications, and drug-drug interaction data are currently flagged as Blocking/High-severity data gaps — TFDA label not yet retrieved, DDI query returned no results.)
Conclusion and Next Steps
Decision: Hold
Rationale: The ADHD indication is supported only by mechanistic/preclinical inference (L4) with zero clinical trials and no ADHD-specific efficacy literature — the retrieved papers address RLS comorbidity and receptor biology, not Rotigotine's clinical effect in ADHD. Combined with a Blocking data gap on TFDA safety labeling, this candidate is not ready to advance past S0.
To proceed, the following is needed:
- DrugBank MOA confirmation (DG002) to formally establish receptor-binding profile relevant to ADHD
- TFDA/German product label retrieval for safety and contraindication review (DG001, currently Blocking)
- Rotigotine-specific preclinical or clinical data in ADHD populations (current literature is indirect/comorbidity-based only)
- Consider parallel evaluation of the schizophrenia candidate (rank 2, L3, "Research Question" stage), which has stronger systematic-review-level evidence and may be a more efficient path forward
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.